Cited by 266SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Open access

Crawford, Katharine H D, Dingens, Adam S, Eguia, Rachel, Wolf, Caitlin R, Wilcox, Naomi, Logue, Jennifer K, Shuey, Kiel, Casto, Amanda M, Fiala, Brooke, Wrenn, Samuel, Pettie, Deleah, King, Neil P, Greninger, Alexander L, Chu, Helen Y, Bloom, Jesse D·2021·The Journal of Infectious Diseases

DOI 10.1093/infdis/jiaa618PMC PMC7543487

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop neutralizing antibodies that target the viral spike protein. In this study, we quantified how levels of these antibodies change in the months after SARS-CoV-2 infection by examining longitudinal samples collected approximately 30–152 days after symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about 4-fold from 1 to 4 months after symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike protein or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/infdis/jiaa618

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Change in neutralizing antibody titer over time. A, Neutralizing antibody titer at 50% inhibition (NT50) for each individual in the study, with facets colored according to disease severity (see key below plot). Facet titles indicate sex (F, female; M, male), age, and participant identifier (PID). Dashed blue line indicates the limit of detection for our assay (NT50 = 20). B, Fold change in NT50 compared with 30-day time point, including only individuals with a neutralizing sample at day 30. P values were calculated using the Wilcoxon signed rank test. C, Distribution of NT50 values at the 3 time points, with box plots colored by disease severity and the blue dashed line indicating the limit of detection as in panel A. P values are indicated when there is a significant difference (P ≤ 0.05) between NT50 values for different disease severity categories at a time point and were calculated using the Wilcoxon rank sum test.CC BY · PubMed Central

Figure 2. Immunoglobulin (Ig) A, IgM, and IgG antibody binding titers over time. A, Longitudinal binding antibody titers for each individual as quantified by area under the curve (AUC) of enzyme-linked immunosorbent assays (ELISAs). Facets are arranged by maximal neutralizing antibody titer at 50% inhibition (NT50) from top left to bottom right, as in Figure 1A. Dashed lines indicate the AUC value for the negative control sample (2017–2018 serum sample pool) for each assay, colored by assay. Abbreviations: F, female; M, male; PID, participant identifier; RBD, receptor-binding domain. B, Correlation plots between AUC for each ELISA and neutralization titer (NT50) for all samples. Vertical dashed line indicates the limit of detection for the neutralization assay; horizontal dashed lines, the AUC values for the negative control sample (2017–2018 serum sample pool) for each assay, colored based on the assay as in A. C, For each antibody type measured, individuals who were symptomatic and required hospitalization as part of their care had significantly higher antibody levels during the first 1–2 months after symptom onset. *P ≤ .05; †P ≤ .01. P values were calculated using the Wilcoxon rank sum test. As in A and B, the dashed line in each facet indicates the AUC value for the negative control sample for each assay, colored by assay.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419

Show all 53 references

Research works printed but not linked: 1

Wu, medRxiv [Preprint]

Sorted by citations

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Self-citation
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
Self-citation
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743
Self-citation
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
Self-citation
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 483
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
Bajema, K. L., Wiegand, R. E., Cuffe, K. M., Patel, S. V., Iachan, R., Lim, T. W., Lee, A., Moyse, D., Havers, F. P., Harding, L., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7976 · Cited by 272
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265
A human coronavirus evolves antigenically to escape antibody immunity
(2021) · doi:10.1371/journal.ppat.1009453 · Cited by 258
Self-citation
A human coronavirus evolves antigenically to escape antibody immunity
Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2020) · doi:10.1101/2020.12.17.423313 · Cited by 258
Self-citation
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244
Self-citation
Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19
Teymouri, M., Mollazadeh, S., Mortazavi, H., Ghale-Noie, Z. N., Keyvani, V., Aghababaei, F., Hamblin, M. R., Abbaszadeh‐Goudarzi, G., Pourghadamyari, H., Hashemian, S. M. R., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153443 · Cited by 228
A simple protein-based surrogate neutralization assay for SARS-CoV-2
Abe, K. T., Li, Z., Samson, R., Samavarchi‐Tehrani, P., Valcourt, E. J., Wood, H., Budylowski, P., Dupuis, A. P., Girardin, R. C., Rathod, B., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142362 · Cited by 200
Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults
Ward, H., Cooke, G., Atchison, C. J., Whitaker, M. D., Elliott, J., Moshe, M., Brown, J. C., Flower, B., Daunt, A., Ainslie, K. E. C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100098 · Cited by 198
A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike
Dadonaite, B., Crawford, K. H. D., Radford, C. E., Farrell, A. G., Yu, T. C., Hannon, W. W., Zhou, P.-P., Andrabi, R., Burton, D. R., Liu, L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.001 · Cited by 186
Self-citation
Prolonged evolution of the human B cell response to SARS-CoV-2 infection
Sakharkar, M., Rappazzo, C. G., Wieland-Alter, W. F., Hsieh, C.-L., Wrapp, D., Esterman, E. S., Kaku, C. I., Wec, A. Z., Geoghegan, J. C., McLellan, J. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg6916 · Cited by 174
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
CD8 + T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19
Mallajosyula, V. V. A., Ganjavi, C., Chakraborty, S., McSween, A. M., Pavlovitch-Bedzyk, A. J., Wilhelmy, J., Nau, A. N., Manohar, M., Nadeau, K. C., & Davis, M. M. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg5669 · Cited by 168
SARS-CoV-2 Seropositivity and Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort StudyPreprint
Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 153
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 151
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 155
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
Pang, N. Y., Pang, A. S., Chow, V. T. K., & Wang, D. Y. (2021) · Military Medical Research · doi:10.1186/s40779-021-00342-3 · Cited by 146
Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020
Self, W. H., Tenforde, M. W., Stubblefield, W. B., Feldstein, L. R., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Prekker, M. E., Brown, S. M., Peltan, I. D., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6947a2 · Cited by 135
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 136
The scientific and ethical feasibility of immunity passports
Brown, R. C. H., Kelly, D. F., Wilkinson, D. J. C., & Savulescu, J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30766-0 · Cited by 136
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 123
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Yu, Y., Wang, M., Zhang, X., Li, S., Lu, Q., Zeng, H., Hou, H., Li, H., Zhang, M., Jiang, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00759-1 · Cited by 122
Antibody Response After SARS-CoV-2 Infection and Implications for Immunity
Arkhipova-Jenkins, I., Helfand, M., Armstrong, C., Gean, E. G., Anderson, J., Paynter, R. A., & Mackey, K. (2021) · Annals of Internal Medicine · doi:10.7326/m20-7547 · Cited by 116
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 102
Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G., van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab172 · Cited by 92
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 95
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 90
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
Favresse, J., Gillot, C., Chiaro, L. D., Eucher, C., Elsen, M., Eeckhoudt, S. V., David, C., Morimont, L., Dogné, J., & Douxfils, J. (2021) · Viruses · doi:10.3390/v13071364 · Cited by 85
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H., Juno, J. A., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100296 · Cited by 81
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 75
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Zhao, F., Zai, X., Zhang, Z., Xu, J., & Chen, W. (2022) · npj Vaccines · doi:10.1038/s41541-022-00597-4 · Cited by 83
Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019
Lee, J.-S., Kim, S. Y., Kim, T. S., Hong, K. H., Ryoo, N.-H., Lee, J., Park, J. H., Cho, S. I., Kim, M. J., Kim, Y.-G., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1421 · Cited by 73
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
Li, C., Yu, D., Wu, X. J., Hong, L., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24230-5 · Cited by 75
Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection
Lin, Y., Wang, G., Shen, Y., Wang, Z.-Y., Zhan, B.-D., Duan, L., Lu, B., Shi, C., Gao, Y., Peng, H.-H., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab255 · Cited by 69
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
Terpos, E., Stellas, D., Rosati, M., Sergentanis, T. Ν., Hu, X., Politou, M., Pappa, V., Ntanasis‐Stathopoulos, I., Karaliota, S., Bear, J., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.010 · Cited by 68
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers
Irsara, C., Egger, A., Prokop, W., Nairz, M., Loacker, L., Sahanic, S., Pizzini, A., Sonnweber, T., Holzer, B., Mayer, W., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0214 · Cited by 65
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
Steenhuis, M., van Mierlo, G. J., Derksen, N. I. L., Heer, P. O., Kruithof, S., Loeff, F. C., Berkhout, L. C., Linty, F., Reusken, C. B. E. M., Reimerink, J. H. J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1285 · Cited by 63
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J. E., Logue, J. K., Corti, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010248 · Cited by 58
Self-citation
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England
Jeffery-Smith, A., Rowland, T. A. J., Patel, M., Whitaker, H., Iyanger, N., Williams, S. V., Giddings, R., Thompson, L., Zavala, M., Aiano, F., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00253-1 · Cited by 60
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
Yu, K. K. Q., Fischinger, S., Smith, M. T., Atyeo, C. G., Cizmeci, D., Wolf, C. R., Layton, E. D., Logue, J. K., Aguilar, M. S., Shuey, K. D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146242 · Cited by 56
Self-citation
Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 59
Expression and characterization of SARS-CoV-2 spike proteins
Schaub, J. M., Chou, C., Kuo, H., Javanmardi, K., Hsieh, C., Goldsmith, J. A., DiVenere, A. M., Le, K. C., Wrapp, D., Byrne, P. O., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00623-0 · Cited by 57
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
Glück, V., Grobecker, S., Tydykov, L., Salzberger, B., Glück, T., Weidlich, T., Bertok, M., Gottwald, C., Wenzel, J. J., Gessner, A., et al. (2021) · Infection · doi:10.1007/s15010-021-01598-6 · Cited by 55
Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
Grandjean, L., Saso, A., Ortiz, A. T., Lam, T., Hatcher, J., Thistlethwayte, R., Harris, M., Best, T., Johnson, M., Wagstaffe, H. R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab607 · Cited by 55
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Swartz, M. D., DeSantis, S. M., Yaseen, A. S., Brito, F. A., Valerio-Shewmaker, M. A., Messiah, S. E., León‐Novelo, L., Kohl, H. W., Pinzon-Gomez, C. L., Hao, T., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac167 · Cited by 56
Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54
Vaccination versus infection with SARS‐CoV‐2: Establishment of a high avidity IgG response versus incomplete avidity maturation
Struck, F., Schreiner, P. A., Staschik, E., Wochinz‐Richter, K., Schulz, S., Soutschek, E., Motz, M., & Bauer, G. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27270 · Cited by 52
Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
Gerhards, C., Thiaucourt, M., Kittel, M., Becker, C., Ast, V., Hetjens, M., Neumaier, M., & Haselmann, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.080 · Cited by 51
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
Markmann, A. J., Giallourou, N., Bhowmik, D. R., Hou, Y. J., Lerner, A., Martinez, D. R., Premkumar, L., Root, H. B., van Duin, D., Napravnik, S., et al. (2021) · mSphere · doi:10.1128/msphere.00275-21 · Cited by 54
Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection
Okuya, K., Hattori, T., Saito, T., Takadate, Y., Sasaki, M., Furuyama, W., Marzi, A., Ohiro, Y., Konno, S., Hattori, T., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01553-21 · Cited by 53
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45
Self-citation
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
Muecksch, F., Wise, H. M., Templeton, K. E., Batchelor, B., Squires, M., McCance, K., JARVIS, L. M., Malloy, K., Furrie, E., Richardson, C., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00090-8 · Cited by 48
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice
Loes, A. N., Gentles, L. E., Greaney, A. J., Crawford, K. H. D., & Bloom, J. D. (2020) · Viruses · doi:10.3390/v12090987 · Cited by 44
Self-citation
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
Sandberg, J. T., Varnaitė, R., Christ, W., Chen, P., Muvva, J. R., Maleki, K. T., García, M., Dzidic, M., Folkesson, E., Skagerberg, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1306 · Cited by 45
Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection
Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S., Ruiz, F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220948120 · Cited by 39
Self-citation
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
Cattaneo, C. M., Cancelli, V., Imberti, L., Dobbs, K., Sottini, A., Pagani, C., Belotti, A., Re, A., Anastasia, A., Quaresima, V., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00546-9 · Cited by 39
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
Yu, Y., Esposito, D., Kang, Z., Lü, J., Remaley, A. T., Giorgi, V. D., Chen, L. N., West, K. A., & Cao, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06629-2 · Cited by 40
The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post–COVID-19 Syndrome in Healthcare Workers
Pereira, C., Harris, B. H. L., Giovannantonio, M. D., Rosadas, C., Short, C.-E. S., Quinlan, R. A., Sureda-Vives, M., Fernández, N., Day-Weber, I., Khan, M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab120 · Cited by 37
Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership
Herrington, D. M., Sanders, J. W., Wierzba, T. F., Alexander‐Miller, M. A., Espeland, M. A., Bertoni, A. G., Mathews, A., Seals, A. L., Munawar, I., Runyon, M. S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06517-6 · Cited by 36
Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34
Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19
Zaidi, S. K., Rizwan, F., Riaz, Q., Siddiqui, A., Khawaja, S., Imam, M., Naz, A., Waheed, S., & Shamsi, T. S. (2020) · Journal of Public Health · doi:10.1093/pubmed/fdaa170 · Cited by 34
Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration
Gouma, S., Weirick, M. E., Bolton, M. J., Arevalo, C. P., Goodwin, E. C., Anderson, E. M., McAllister, C. M., Christensen, S. R., Dunbar, D., Fiore, D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150449 · Cited by 30
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination
Fernández‐González, M., Agulló, V., Padilla, S., García, J. A., García‐Abellán, J., Botella, Á., Mascarell, P., Ruiz‐García, M., Masiá, M., & Gutiérrez, F. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1021 · Cited by 34
Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection
Yan, L., Liu, P., Li, X.-G., Zhou, S.-J., Li, H., Wang, Z.-Y., Shen, F., Lu, B., Long, Y., Xiao, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.803031 · Cited by 36
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
Rosati, M., Terpos, E., Ntanasis‐Stathopoulos, I., Agarwal, M., Bear, J., Burns, R. T., Hu, X., Korompoki, E., Donohue, D. E., Venzon, D. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793953 · Cited by 34
Impact of reproduction number on the multiwave spreading dynamics of COVID-19 with temporary immunity: A mathematical model
Shayak, B., Sharma, M., Gaur, M., & Mishra, A. K. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.018 · Cited by 31
What do we know about the antibody responses to SARS-CoV-2?
Lagunas‐Rangel, F. A., & Chávez‐Valencia, V. (2021) · Immunobiology · doi:10.1016/j.imbio.2021.152054 · Cited by 32
SARS–CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges
McGill, A. R., Khalil, R., Dutta, R., Green, R. J., Howell, M., Mohapatra, S., & Mohapatra, S. S. (2021) · Infectious Disease Reports · doi:10.3390/idr13010013 · Cited by 30
Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study
Horton, D. B., Barrett, E. S., Roy, J., Gennaro, M. L., Andrews, T., Greenberg, P. J., Bruiners, N., Datta, P., Ukey, R., Velusamy, S. K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab411 · Cited by 28
The role and uses of antibodies in COVID-19 infections: a living review
Scourfield, D. O., Reed, S. G., Quastel, M. N., Alderson, J., Bart, V. M. T., Crespo, A. T., Jones, R. E., Pring, E., Richter, F. C., Ahern, D., et al. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab003 · Cited by 30
A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens
Upreti, S., & Samant, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03323-w · Cited by 29
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27
Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile
Law, J. C., Koh, W. H., Budylowski, P., Lin, J., Yue, F., Abe, K. T., Rathod, B., Girard, M., Li, Z., Rini, J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001067 · Cited by 27
A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
Luo, Y. R., Yun, C., Chakraborty, I., Wu, A. H. B., & Lynch, K. L. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-21 · Cited by 24
IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers
Vandergaast, R., Carey, T. S., Reiter, S., Lathrum, C., Lech, P. J., Gnanadurai, C. W., Haselton, M., Buehler, J., Narjari, R., Schnebeck, L., et al. (2021) · mSphere · doi:10.1128/msphere.00170-21 · Cited by 27
Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019
Noh, J. Y., Kwak, J.-E., Yang, J., Hwang, S. Y., Yoon, J. G., Seong, H., Hyun, H., Lim, C. S., Yoon, S., Ryou, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab124 · Cited by 24
Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis
Savage, H. R., Santos, V. S., Edwards, T., Giorgi, E., Krishna, S., Planche, T., Staines, H. M., Fitchett, J. R. A., Kirwan, D. E., Cubas-Atienzar, A. I., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009551 · Cited by 24
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
Tiyo, B. T., Schmitz, G. J. H., Ortega, M. M., da Silva, L. T., de Almeida, A., Oshiro, T. M., & Duarte, A. J. D. S. (2021) · Life · doi:10.3390/life11111152 · Cited by 28
Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., & Menzies, N. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac438 · Cited by 25
The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 29
Self-citation
Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays
Renard, N., Daniel, S., Cayet, N., Pecquet, M., Raymond, F., Pons, S., Lupo, J., Tourneur, C., Pretis, C., Gerez, G., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02292-20 · Cited by 27
The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
Guenthoer, J., Garrett, M. E., Lilly, M., Depierreux, D., Ruiz, F., Chi, M., Stoddard, C. I., Chohan, V., Yaffe, Z. A., Sung, K., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012383 · Cited by 27
Self-citation
Effect of ArtemiC in patients with COVID‐19: A Phase II prospective study
Hellou, E., Mohsin, J., Elemy, A., Hakim, F., Hellou, M. M., & Hamoud, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17337 · Cited by 22
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P. S., Mori, D. A., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., Holubar, M. K., et al. (2022) · eLife · doi:10.7554/elife.77943 · Cited by 30
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
Palumbo, G. A., Cambria, D., Spina, E. L., Duminuco, A., Laneri, A., Longo, A., Vetro, C., Giallongo, S., Romano, A., Raimondo, F. D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117815 · Cited by 21
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 21
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21

Authors: Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., Pettie, D., King, N. P., Greninger, A. L., Chu, H. Y., & Bloom, J. D.
Affiliations: University of Washington (US)
Fred Hutch Cancer Center (US)
Howard Hughes Medical Institute (US)
Corresponding author: Chu, Helen Y
Bloom, Jesse D
ORCID: Crawford, Katharine H D
Dingens, Adam S
Eguia, Rachel
Wolf, Caitlin R
Logue, Jennifer K
Shuey, Kiel
Casto, Amanda M
Fiala, Brooke
Wrenn, Samuel
Pettie, Deleah
King, Neil P
Greninger, Alexander L
Chu, Helen Y
Bloom, Jesse D
Venue: The Journal of Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2020-09-30
Volume: 223
Issue: 2
Pages: 197-205
ISSN: 0022-1899 (ISSN-L)
1537-6613
DOI: 10.1093/infdis/jiaa618
PMC: PMC7543487
OpenAlex: W3091039991
Cited by: 265
References: 53
Citations by year: 2026: 5 · 2025: 13 · 2024: 16 · 2023: 32 · 2022: 58 · 2021: 120 · 2020: 21
FWCI: 7.58
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor, 1 d)
Locations: The Journal of Infectious Diseases (publishedVersion, cc-by)
medRxiv (acceptedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: National Institute of Allergy and Infectious Diseases (R01AI141707, F30AI149928)
National Institutes of Health
Bill and Melinda Gates Foundation (OPP1156262)
Burroughs Wellcome Fund
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody titer decline, spike protein, receptor binding domain, humoral immune response, long-term immunity, asymptomatic infection
MeSH terms: COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Female, Humans, Male, Middle Aged, Prospective Studies, Time Factors, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks